Cobra Biomanufacturing Plc. (AIM : CBF) has signed a contract with the Australian company Replikun Biotech to support the development of an innovative gene therapy method. Cobra will construct and establish a packaging cell line producing KUN-GMCSF, a potent and novel gene therapy system for the treatment of cancer.
